Ractigen Therapeutics, a leader in biotechnology, has announced a significant breakthrough in obesity treatment with its small activating RNA (saRNA) candidate, LiCO-saUcp1. This announcement was made during the American Diabetes Association (ADA) 86th Scientific Sessions held in New Orleans, Louisiana. The therapy promises to revolutionize obesity management by effectively converting white fat into calorie-burning brown fat, thereby promoting substantial fat loss while preserving lean muscle mass.
Innovative Approach to Obesity Treatment
LiCO-saUcp1, developed using Ractigen’s proprietary Lipid-Conjugated Oligonucleotide (LiCO™) delivery platform, targets the Ucp1 gene, which is crucial for metabolic thermogenesis. This gene has been considered undruggable by traditional pharmaceuticals, but Ractigen’s approach successfully activates it, offering a new frontier in obesity control. The therapy not only ensures high-quality weight loss but also prevents the common issue of weight rebound after treatment cessation.
Promising Preclinical Results
In preclinical models of diet-induced obesity, LiCO-saUcp1 demonstrated a 45% reduction in fat mass while maintaining lean muscle. This contrasts sharply with standard treatments like semaglutide, which resulted in a 19% loss of lean mass. Furthermore, animals treated with LiCO-saUcp1 maintained their reduced body weight for two months post-treatment, unlike those on semaglutide who experienced rapid weight regain.
Synergy and Additional Health Benefits
When combined with semaglutide, LiCO-saUcp1 enhanced fat mass reduction to 69% without exacerbating muscle depletion. Additionally, the therapy significantly improved liver health by reducing liver triglycerides by up to 79%, addressing issues like hepatic steatosis.
Future Prospects
Ractigen Therapeutics is positioning LiCO-saUcp1 as a standalone treatment or as a complementary therapy to existing incretin treatments. This innovative approach underscores the potential of RNA activation in addressing complex health challenges, offering hope for more effective obesity management solutions.
The full abstract of the study is available online through the journal Diabetes® website, and further details were presented at the ADA conference by Dr. Moorim Kang, Ractigen’s Chief Technology Officer.
Original reporting: KTBS 3 (Shreveport) — read the source article.
